Compile Data Set for Download or QSAR

Found 302 hits Enz. Inhib. hit(s) with all data for entry = 8754   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM417008 ((+)-N-(5-(1-amino-1-(6-cyanopyridin-2-yl)-3-cyclop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(n1)C#N)C(F)(F)F Show InChI InChI=1S/C30H27F4N7O/c31-23-10-9-20(29(37,12-11-18-7-8-18)26-6-2-4-21(17-36)38-26)14-24(23)39-28(42)25-15-27(30(32,33)34)40-41(25)22-5-1-3-19(13-22)16-35/h1-6,9-10,13-15,18H,7-8,11-12,16,35,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417009 (1-(3-carbamimidoylphenyl)-N-(5-((+-)-3-cyclopropyl...) Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccnc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(c2)C(N)=N)C(F)(F)F)c1 Show InChI InChI=1S/C33H35F4N7O2S/c1-31(2,3)47(46)43-32(14-13-20-9-10-20,23-7-5-15-40-19-23)22-11-12-25(34)26(17-22)41-30(45)27-18-28(33(35,36)37)42-44(27)24-8-4-6-21(16-24)29(38)39/h4-8,11-12,15-20,43H,9-10,13-14H2,1-3H3,(H3,38,39)(H,41,45)/t32?,47-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417012 ((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F Show InChI InChI=1S/C31H27F4N7O/c32-24-11-10-22(30(39,13-12-18-4-5-18)21-8-6-19(17-36)7-9-21)15-25(24)40-29(43)26-16-27(31(33,34)35)41-42(26)23-3-1-2-20(14-23)28(37)38/h1-3,6-11,14-16,18H,4-5,12-13,39H2,(H3,37,38)(H,40,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417013 (1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...) Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O)C(F)(F)F Show InChI InChI=1S/C31H26F4N6O2/c32-23-10-8-20(25(11-6-18-4-5-18)40-14-2-1-3-28(40)42)15-24(23)38-30(43)26-17-27(31(33,34)35)39-41(26)21-9-7-19-12-13-37-29(36)22(19)16-21/h1-3,7-10,12-18,25H,4-6,11H2,(H2,36,37)(H,38,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417014 ((+-)-N-(5-(1-amino-1-(3-carbamoylphenyl)-3-cyclopr...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C(N)=O)C(F)(F)F Show InChI InChI=1S/C31H30F4N6O2/c32-24-10-9-22(30(38,12-11-18-7-8-18)21-5-2-4-20(14-21)28(37)42)15-25(24)39-29(43)26-16-27(31(33,34)35)40-41(26)23-6-1-3-19(13-23)17-36/h1-6,9-10,13-16,18H,7-8,11-12,17,36,38H2,(H2,37,42)(H,39,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417016 ((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)[C@H](CCC1CC1)n1ccccc1=O)C(F)(F)F |r| Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-20(24(12-9-18-7-8-18)37-13-2-1-6-27(37)39)15-23(22)35-28(40)25-16-26(29(31,32)33)36-38(25)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,24H,7-9,12,17,34H2,(H,35,40)/t24-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417018 ((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N7O/c30-22-9-8-19(28(36,11-10-17-6-7-17)20-4-2-12-37-16-20)14-23(22)38-27(41)24-15-25(29(31,32)33)39-40(24)21-5-1-3-18(13-21)26(34)35/h1-5,8-9,12-17H,6-7,10-11,36H2,(H3,34,35)(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417019 ((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)[C@@H](CCC1CC1)n1ccccc1=O)C(F)(F)F |r| Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-20(24(12-9-18-7-8-18)37-13-2-1-6-27(37)39)15-23(22)35-28(40)25-16-26(29(31,32)33)36-38(25)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,24H,7-9,12,17,34H2,(H,35,40)/t24-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417020 (HCl salt of (+-)-1-(3-carbamimidoylphenyl)-N-(5-((...) Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)[C@@H](NCC1CC1)c1ccccc1)C(F)(F)F |r| Show InChI InChI=1S/C29H26F4N6O/c30-22-12-11-19(26(36-16-17-9-10-17)18-5-2-1-3-6-18)14-23(22)37-28(40)24-15-25(29(31,32)33)38-39(24)21-8-4-7-20(13-21)27(34)35/h1-8,11-15,17,26,36H,9-10,16H2,(H3,34,35)(H,37,40)/t26-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417021 ((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(nc1)C(N)=O)C(F)(F)F Show InChI InChI=1S/C30H29F4N7O2/c31-22-8-6-19(29(37,11-10-17-4-5-17)20-7-9-23(27(36)42)38-16-20)13-24(22)39-28(43)25-14-26(30(32,33)34)40-41(25)21-3-1-2-18(12-21)15-35/h1-3,6-9,12-14,16-17H,4-5,10-11,15,35,37H2,(H2,36,42)(H,39,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417022 ((+)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropyl...) Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C30H25F4N7O/c31-23-6-4-20(27(38-16-17-1-2-17)19-7-10-36-11-8-19)13-24(23)39-29(42)25-15-26(30(32,33)34)40-41(25)21-5-3-18-9-12-37-28(35)22(18)14-21/h3-15,17,27,38H,1-2,16H2,(H2,35,37)(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417023 ((+)-N-(5-(1-amino-1-(4-carbamoylphenyl)-3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C(N)=O)C(F)(F)F Show InChI InChI=1S/C31H30F4N6O2/c32-24-11-10-22(30(38,13-12-18-4-5-18)21-8-6-20(7-9-21)28(37)42)15-25(24)39-29(43)26-16-27(31(33,34)35)40-41(26)23-3-1-2-19(14-23)17-36/h1-3,6-11,14-16,18H,4-5,12-13,17,36,38H2,(H2,37,42)(H,39,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417024 ((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C29H28F4N6O/c30-23-7-6-21(28(35,11-8-18-4-5-18)20-9-12-36-13-10-20)15-24(23)37-27(40)25-16-26(29(31,32)33)38-39(25)22-3-1-2-19(14-22)17-34/h1-3,6-7,9-10,12-16,18H,4-5,8,11,17,34-35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417025 ((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)N1CCCCC1=O)C(F)(F)F Show InChI InChI=1S/C29H31F4N5O2/c30-22-11-10-20(24(12-9-18-7-8-18)37-13-2-1-6-27(37)39)15-23(22)35-28(40)25-16-26(29(31,32)33)36-38(25)21-5-3-4-19(14-21)17-34/h3-5,10-11,14-16,18,24H,1-2,6-9,12-13,17,34H2,(H,35,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417026 ((+-)-1-(3-(aminomethyl)phenyl)-N5-(5-((cyclopropyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(N)=O Show InChI InChI=1S/C29H29FN6O2/c30-23-12-11-21(27(33-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)34-29(38)26-15-25(28(32)37)35-36(26)22-8-4-5-19(13-22)16-31/h1-8,11-15,18,27,33H,9-10,16-17,31H2,(H2,32,37)(H,34,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417027 (1-(3-(aminomethyl)phenyl)-N-(5-((+-)-3-cyclopropyl...) Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1cccnc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C33H36F4N6O2S/c1-31(2,3)46(45)42-32(14-13-21-9-10-21,24-7-5-15-39-20-24)23-11-12-26(34)27(17-23)40-30(44)28-18-29(33(35,36)37)41-43(28)25-8-4-6-22(16-25)19-38/h4-8,11-12,15-18,20-21,42H,9-10,13-14,19,38H2,1-3H3,(H,40,44)/t32?,46-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417028 (1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...) Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccncc1=O)C(F)(F)F Show InChI InChI=1S/C30H25F4N7O2/c31-22-7-5-19(24(8-3-17-1-2-17)40-12-11-36-16-27(40)42)13-23(22)38-29(43)25-15-26(30(32,33)34)39-41(25)20-6-4-18-9-10-37-28(35)21(18)14-20/h4-7,9-17,24H,1-3,8H2,(H2,35,37)(H,38,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417031 ((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...) Show SMILES Cc1cc(ccn1)C(N)(CCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F4N6O/c1-18-13-22(10-12-37-18)29(36,11-9-19-5-6-19)21-7-8-24(31)25(15-21)38-28(41)26-16-27(30(32,33)34)39-40(26)23-4-2-3-20(14-23)17-35/h2-4,7-8,10,12-16,19H,5-6,9,11,17,35-36H2,1H3,(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM417032 (1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...) Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccc(=O)[nH]c1=O)C(F)(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416739 (1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropylethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)N(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)27-18-26(37(35-27)25-11-4-6-21(16-25)19-33)28(38)34-22-7-5-10-24(17-22)36(15-14-20-12-13-20)23-8-2-1-3-9-23/h1-11,16-18,20H,12-15,19,33H2,(H,34,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416742 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(NCC2CC2)c2ccccc2)c1F)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-26-22(27(35-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)36-28(39)24-15-25(29(31,32)33)37-38(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27,35H,12-13,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416745 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1nccs1)C(F)(F)F Show InChI InChI=1S/C26H24F3N5O2S/c27-26(28,29)22-13-21(34(33-22)20-6-1-3-17(11-20)14-30)24(35)32-19-5-2-4-18(12-19)23(25-31-9-10-37-25)36-15-16-7-8-16/h1-6,9-13,16,23H,7-8,14-15,30H2,(H,32,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416747 (1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H26F4N4O2/c30-23-12-11-21(27(39-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)35-28(38)25-15-26(29(31,32)33)36-37(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27H,9-10,16-17,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416748 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)22-8-3-5-19(13-22)16-32)27(38)35-21-7-4-6-20(14-21)26(34-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26,34H,10-11,16-17,32H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416757 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(1...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)n1ccnc1)C(F)(F)F Show InChI InChI=1S/C27H27F3N6O/c28-27(29,30)25-15-24(36(34-25)22-6-1-3-19(13-22)16-31)26(37)33-21-5-2-4-20(14-21)23(10-9-18-7-8-18)35-12-11-32-17-35/h1-6,11-15,17-18,23H,7-10,16,31H2,(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416760 ((E/Z)-1-(3-(Aminomethyl)phenyl)-N-(3-(3-cyclopropy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(=C\CC1CC1)\c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H27F3N4O/c31-30(32,33)28-18-27(37(36-28)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)26(15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,15-18,20H,12-14,19,34H2,(H,35,38)/b26-15+	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416763 (1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(Cc2ccccc2NCC2CC2)c1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)27-16-26(37(36-27)24-9-4-6-21(15-24)17-33)28(38)35-23-8-3-5-20(14-23)13-22-7-1-2-10-25(22)34-18-19-11-12-19/h1-10,14-16,19,34H,11-13,17-18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416764 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)23-6-1-3-19(13-23)16-32)27(38)35-22-5-2-4-21(14-22)26(34-17-18-7-8-18)20-9-11-33-12-10-20/h1-6,9-15,18,26,34H,7-8,16-17,32H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416766 (1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropyletho...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)28(22-7-2-1-3-8-22)39-15-14-20-12-13-20/h1-11,16-18,20,28H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416767 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-24(37(36-26)23-8-3-5-20(15-23)18-33)27(38)35-22-7-4-6-21(16-22)28(39,13-12-19-10-11-19)25-9-1-2-14-34-25/h1-9,14-17,19,39H,10-13,18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416774 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-25(37(36-26)24-6-1-3-20(15-24)18-33)27(38)35-23-5-2-4-22(16-23)28(39,12-9-19-7-8-19)21-10-13-34-14-11-21/h1-6,10-11,13-17,19,39H,7-9,12,18,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416775 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416777 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cn[nH]c1)C(F)(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416779 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(OCC2CC2)c2ccccc2)c1F)C(F)(F)F Show InChI InChI=1S/C29H26F4N4O2/c30-26-22(27(39-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)35-28(38)24-15-25(29(31,32)33)36-37(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27H,12-13,16-17,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416780 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1nccs1)C(F)(F)F Show InChI InChI=1S/C26H25F3N6OS/c27-26(28,29)22-13-21(35(34-22)20-6-1-3-17(11-20)14-30)24(36)33-19-5-2-4-18(12-19)23(25-31-9-10-37-25)32-15-16-7-8-16/h1-6,9-13,16,23,32H,7-8,14-15,30H2,(H,33,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416782 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES COc1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O2/c1-40-25-10-4-7-22(15-25)28(35-18-19-11-12-19)21-6-3-8-23(14-21)36-29(39)26-16-27(30(31,32)33)37-38(26)24-9-2-5-20(13-24)17-34/h2-10,13-16,19,28,35H,11-12,17-18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416783 (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc2ccccc2c1)C(F)(F)F Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)28-10-3-5-22(15-28)19-37)32(42)39-27-9-4-8-25(17-27)31(38-20-21-11-12-21)26-14-13-23-6-1-2-7-24(23)16-26/h1-10,13-18,21,31,38H,11-12,19-20,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416784 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F4N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416785 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES Cc1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O/c1-19-5-2-7-22(13-19)28(35-18-20-11-12-20)23-8-4-9-24(15-23)36-29(39)26-16-27(30(31,32)33)37-38(26)25-10-3-6-21(14-25)17-34/h2-10,13-16,20,28,35H,11-12,17-18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416786 (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc2ccccc12)C(F)(F)F Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)26-11-3-6-22(16-26)19-37)32(42)39-25-10-4-9-24(17-25)31(38-20-21-14-15-21)28-13-5-8-23-7-1-2-12-27(23)28/h1-13,16-18,21,31,38H,14-15,19-20,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416787 (1-(3-(aminomethyl)phenyl)-N-(3-cyclopropyl-5-((cyc...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(Cc2ccccc2NCC2CC2)cc(c1)C1CC1)C(F)(F)F Show InChI InChI=1S/C32H32F3N5O/c33-32(34,35)30-17-29(40(39-30)27-6-3-4-21(15-27)18-36)31(41)38-26-14-22(13-25(16-26)23-10-11-23)12-24-5-1-2-7-28(24)37-19-20-8-9-20/h1-7,13-17,20,23,37H,8-12,18-19,36H2,(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416788 (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(c1)C(F)(F)F)C(F)(F)F Show InChI InChI=1S/C30H27F6N5O/c31-29(32,33)22-7-2-5-20(13-22)27(38-17-18-10-11-18)21-6-3-8-23(14-21)39-28(42)25-15-26(30(34,35)36)40-41(25)24-9-1-4-19(12-24)16-37/h1-9,12-15,18,27,38H,10-11,16-17,37H2,(H,39,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416789 (1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F Show InChI InChI=1S/C29H28F4N6O/c30-23-11-8-20(27(36-16-17-4-5-17)19-6-9-21(35)10-7-19)13-24(23)37-28(40)25-14-26(29(31,32)33)38-39(25)22-3-1-2-18(12-22)15-34/h1-3,6-14,17,27,36H,4-5,15-16,34-35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416790 (1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1Cl)C(NCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26ClF3N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416791 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(cc1)S(N)(=O)=O)C(F)(F)F Show InChI InChI=1S/C29H29F3N6O3S/c30-29(31,32)26-15-25(38(37-26)23-6-1-3-19(13-23)16-33)28(39)36-22-5-2-4-21(14-22)27(35-17-18-7-8-18)20-9-11-24(12-10-20)42(34,40)41/h1-6,9-15,18,27,35H,7-8,16-17,33H2,(H,36,39)(H2,34,40,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416792 (1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(N)c1)C(F)(F)F Show InChI InChI=1S/C29H28F4N6O/c30-23-10-9-20(27(36-16-17-7-8-17)19-4-2-5-21(35)12-19)13-24(23)37-28(40)25-14-26(29(31,32)33)38-39(25)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27,36H,7-8,15-16,34-35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416794 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10329260 (2019) BindingDB Entry DOI: 10.7270/Q2R78HM5
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>

Jump to: